As medical breakthroughs accelerate, the discussions around FDA regulations and safety standards rarely keep pace in clarity. They’re often buried in jargon that makes an already complex system feel even further out of reach. Standing at the center of this complexity is Alan Schwartz, President/Founder of mdi Consultants, bringing clarity, rigor, and purpose to one of the industry’s most misunderstood spaces.
With decades of experience from his early days as an FDA investigator to leading mdi Consultants, Alan has seen how overwhelming the regulatory journey can be for companies eager to bring new technologies to life. His mission has remained simple: make compliance understandable, achievable, and rooted in genuine responsibility.
For Alan, regulatory consulting isn’t just about approvals or audits. It’s about trust, patient safety, and helping innovators move confidently from idea to impact. Through a blend of deep expertise and unwavering integrity, he reminds the industry that compliance isn’t a barrier to progress, the foundation that makes meaningful innovation possible.
A Leader Shaping the Future of Compliance
In 2026, as the regulatory landscape transforms faster than ever before, Alan Schwartz stands out as one of the most influential leaders advancing FDA compliance and quality assurance. His leadership of mdi Consultants has cemented a legacy defined by unwavering service quality, ethical responsibility, and the rare ability to anticipate regulatory outcomes before they occur.
From pioneering fixed-price consulting models to guaranteeing ISO certifications and 510(k) approvals (when recommendations and guidance are adhered to and followed), Schwartz’s philosophy blends risk ownership, accountability, and deep technical mastery. His influence has reached beyond organizations, impacting the very standards of how consulting firms serve the life sciences and medical device sector.
Innovation in a Highly Synchronized World
In FDA-regulated industries, innovation does not mean breaking norms; it means understanding them so thoroughly that better, faster, more efficient pathways emerge. Schwartz defines innovation not as technology alone but as the ability to anticipate regulatory trajectories and recalibrate client strategies accordingly.
Recognizing that FDA changes rarely happen overnight, Schwartz’s team focuses on reading emerging patterns, analyzing reviewer interactions, and anticipating shifts long before new guidance is released. This proactive approach reduces client risk, cost, and time-to-market.
A Model That Changed the Industry: Fixed-Price Consulting
The mdi Consultant’s fixed-price model emerged from Schwartz’s early frustration with the hourly billing culture, intensified by attorneys who started the billing clock as soon as they picked up the phone. Instead, Schwartz introduced transparency, predictability, and accountability: clients knew costs upfront, while mdi Consultant assumed execution risk. This model drove trust, accelerated growth, and allowed smaller companies, often the most resource-constrained, to enter regulated markets with confidence.
Schwartz’s approach also shifted the power back to clients, ensuring they paid for outcomes rather than time spent. It eliminated hidden fees and encouraged deeper, more collaborative relationships between teams. Internally, the model pushed mdi to refine its processes, strengthen documentation systems, and build highly efficient project teams. Over time, competitors began adopting similar structures, acknowledging the model’s effectiveness. Today, fixed-price consulting stands as one of Schwartz’s most influential contributions to the regulatory consulting field.
| Innovation in FDA Compliance | |
|---|---|
| Element | What It Means at mdi |
| Regulatory Foresight | Predicting policy trends before official guidance |
| Fixed-Price Model | Transparency, client trust, and reduced financial risk |
| Technical Expertise | Thousands of 510(k)/QSR/cGMP and ISO submissions handled |
| Cybersecurity Focus | ISO 27001 + FDA-aligned penetration testing |
| Global Strategy | U.S. Agent for 500+ worldwide manufacturers |
Building a Team of Strong, Intelligent, High-Integrity Experts
Schwartz credits mdi’s global influence not to his individual leadership alone, but to the strength and longevity of his team. His career has been defined by recruiting smart, disciplined professionals who have been with the company for 20, 30, or even 40+ years.
His philosophy is simple:
“When you find intelligent people who elevate your mission, never let them go.”
mdi’s ability to maintain personalization while scaling to 1000+ global clients is powered by this stable and deeply experienced workforce.
The Science Behind Confidence
mdi Consultants is one of the few firms confident enough to guarantee first-time ISO certifications or 510(k) approvals, provided clients follow every recommendation. This assurance is not a marketing promise; it is built on a proven scientific and regulatory foundation.
The Foundation of This Confidence:
- Deep Insight Into FDA Reviewer Expectations
- Decades of experience and close interaction with FDA reviewers allow mdi to anticipate questions, concerns, and documentation standards before files are even submitted. Their team understands how reviewers think and what triggers delays or rejections.
- Proven Quality-System Design Methods
- mdi’s systems are not theoretical; they are engineered through real-world experience across 1000+ companies. Their frameworks consistently meet regulatory expectations for safety, effectiveness, and risk control.
- Rigorous Documentation and Risk Management
- Every line of documentation is built with traceability, clarity, and defensibility in mind. From design controls to validation, mdi’s meticulous approach minimizes gaps that typically lead to regulatory pushback.
- A Culture of Accountability and Transparency
- The firm’s internal culture is rooted in ownership taking full responsibility for every recommendation, review, and submission. This reinforces consistency, accuracy, and trust across all project stages.
- Clear Tracking When Clients Deviate From Recommendations
- If a client chooses a different path, mdi documents every decision, justification, and outcome. This ensures complete clarity, protects process integrity, and provides a defensible trail should the FDA or a Client raise questions later.
- A Results-Driven Approach Refined Over Four Decades
- With thousands of successful 510(k), ISO, and global regulatory submissions, mdi has built a methodology that is both highly structured and adaptable to new technologies, markets, and regulatory shifts.
Global Regulatory Navigation and U.S. Agent Expertise
As a designated U.S. Agent for international manufacturers, Schwartz and his team guide non-U.S. companies through one of the most complex and closely monitored regulatory systems in the world. Their role extends far beyond facilitating FDA communication; they help organizations interpret regulatory expectations across different cultures, geographies, and technological landscapes.
By clearly defining responsibilities and setting transparent expectations early, mdi ensures foreign manufacturers understand both requirements and potential risks long before their products reach the U.S. market.
Alan Schwartz’s deep experience with cross-border regulatory challenges allows them to simplify traditionally overwhelming processes, giving companies confidence as they scale globally. Whether advising first-time entrants or established international firms, mdi provides a stabilizing presence translating complex U.S. standards into actionable strategies.
This guidance becomes especially crucial for companies unfamiliar with American documentation practices, inspection styles, and enforcement trends. By bridging cultural, technical, and regulatory gaps, mdi helps global manufacturers avoid delays, misunderstandings, and costly compliance failures. Ultimately, they empower foreign companies to launch safely, successfully, and with long-term regulatory resilience.
The Next Frontier: Cybersecurity & Regulatory Foresight
As connected and software-driven devices reshape healthcare, Schwartz sees cybersecurity and evolving global regulations as the next major compliance challenges. With new FDA requirements such as the FD&C Act Section 524B, manufacturers now face heightened expectations that many struggle to meet.
Through its partnership with a specialized cybersecurity firm, mdi Consultant delivers advanced penetration testing and ISO 27001–aligned guidance, ensuring clients stay secure, compliant, and focused on patient safety. This unified approach helps companies strengthen their product resilience long before vulnerabilities become regulatory or operational risks.
At the same time, mdi Consultants by Alan, in close collaboration with the FDA and EU reviewers, allows the team to spot emerging regulatory shifts before they become formal policy. This foresight helps companies avoid delays, reduce redesigns, and stay ahead of rapidly changing global standards. It also empowers manufacturers to plan smarter, invest strategically, and approach innovation with greater confidence.
Together, these capabilities position Alan as a leader helping companies navigate complexity, anticipate the future, and bring safer, compliant technologies to market with clarity and control.
A Success Story That Demonstrates True Regulatory Mastery
Among the thousands of submissions mdi has managed, one case remains a defining example of the firm’s depth and capability: overturning an FDA Non-Substantial Equivalence (NSE) determination for a highly advanced Gamma Rays Stereotactic Radiation Therapy System. For most companies, an NSE is the end of the road. For mdi, it became a challenge to re-strategize, re-document, and prove the science with greater clarity.
Under Alan Schwartz’s leadership, the team dissected every technical detail, reconstructed the substantial equivalence argument, and built a stronger, data-backed narrative that directly addressed FDA concerns. Alan’s experience as a former FDA investigator played a critical role; he instinctively understood the agency’s mindset, the reviewers’ hesitations, and the precise evidence needed to shift the outcome.
mdi ultimately succeeded not once, but twice in overturning NSE decisions for complex medical technology devices. These victories were not only regulatory achievements; they were proof of Alan’s strategic foresight, scientific rigor, and unwavering commitment to seeing a client’s breakthrough technology reach patients who need it.
These cases continue to stand as a benchmark of Alan’s precision, resilience, and mastery in navigating the most challenging scientific and regulatory landscapes.
| Client Impact Framework | |
|---|---|
| Area | mdi Contribution |
| Time-to-Market | Faster submissions with strategic foresight |
| Compliance Accuracy | Avoiding costly redesigns and audits |
| Regulatory Navigation | Support across FDA, EU MDR, ISO |
| Cybersecurity | Penetration testing + risk mitigation |
| Global Expansion | Smooth U.S. entry for foreign manufacturers |
Legacy of Leadership and Impact
Over the past five decades, mdi Consultants has built a reputation rooted in expertise, trust, and industry-shaping achievements. Together, these milestones reflect a journey of sustained growth, global influence, and unwavering commitment to regulatory excellence.
- Founding mdi Consultants nearly five decades ago
- Growing a global team with tenures of 20–45 years
- Guiding 500+ companies through FDA, EU, and ISO compliance
- Leading one of the industry’s first fixed-price consulting models
- Transforming mdi into a trusted U.S. Agent for international manufacturers
- Becoming one of the foremost influencers in FDA compliance for medical devices and pharmaceuticals.
Future Outlook: Leading Through the Next Wave of Disruption
Schwartz identifies digital health, AI-driven diagnostics, robotics, and cybersecurity as the key disruptors that will reshape the medical device landscape over the next 3–5 years. Yet he emphasizes that despite these rapid advancements, the regulatory foundation remains unchanged: every innovation must ultimately prove safety and effectiveness.
Guided by this principle, mdi’s forward-looking strategy focuses on staying ahead of emerging technologies while preserving the scientific rigor, precision, and compliance standards that define FDA success. This balance of innovation on the horizon, fundamentals at the core continues to shape mdi’s roadmap for the future.
| Leadership Philosophy | |
|---|---|
| Pillar | Description |
| Team Longevity | Staff with 20–45 years of experience |
| Intellectual Strength | Hiring “smart, strong, intelligent” professionals |
| Responsibility Sharing | Clear client + consultant task expectations |
| Rigor | Data-driven, documentation-first approach |
| Results | First-time approval and certification guarantees |
Five Key Takeaways
- Alan Schwartz has transformed FDA compliance consulting through foresight-driven innovation, even within a traditionally rigid regulatory environment.
- mdi’s fixed-price model redefined industry trust, offering transparency and accountability rarely seen in regulatory consulting.
- With a global footprint and a team of long-tenured experts, Schwartz has scaled high-touch, personalized regulatory guidance to 500+ clients worldwide.
- Cybersecurity has become one of central pillars of mdi’s future strategy, addressing the growing risks associated with connected medical devices.
- Schwartz’s leadership philosophy, built on intelligence, integrity, and strong teamwork, continues to shape mdi as a global benchmark in quality assurance and regulatory excellence.
